Atossa Therapeutics Inc (ATOS)
1.51
+0.12
(+8.63%)
USD |
NASDAQ |
Sep 27, 16:00
1.49
-0.02
(-1.32%)
After-Hours: 20:00
Atossa Therapeutics Research and Development Expense (Quarterly): 3.553M for June 30, 2024
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2024 | 3.553M |
| March 31, 2024 | 3.748M |
| December 31, 2023 | 5.654M |
| September 30, 2023 | 4.467M |
| June 30, 2023 | 3.705M |
| March 31, 2023 | 3.508M |
| December 31, 2022 | 4.986M |
| September 30, 2022 | 5.16M |
| June 30, 2022 | 3.433M |
| March 31, 2022 | 1.499M |
| December 31, 2021 | 1.827M |
| September 30, 2021 | 2.206M |
| June 30, 2021 | 3.799M |
| March 31, 2021 | 1.379M |
| December 31, 2020 | 2.357M |
| September 30, 2020 | 1.659M |
| June 30, 2020 | 1.653M |
| March 31, 2020 | 0.9386M |
| December 31, 2019 | 0.898M |
| September 30, 2019 | 1.684M |
| June 30, 2019 | 2.612M |
| March 31, 2019 | 1.451M |
| December 31, 2018 | 0.8494M |
| September 30, 2018 | 1.422M |
| June 30, 2018 | 1.468M |
| Date | Value |
|---|---|
| March 31, 2018 | 0.471M |
| December 31, 2017 | 0.2172M |
| September 30, 2017 | 0.7425M |
| June 30, 2017 | 0.8241M |
| March 31, 2017 | 0.5443M |
| December 31, 2016 | 0.3665M |
| September 30, 2016 | 0.085M |
| June 30, 2016 | 0.169M |
| March 31, 2016 | 0.15M |
| December 31, 2015 | 0.4714M |
| September 30, 2015 | 0.949M |
| June 30, 2015 | 0.3735M |
| March 31, 2015 | 0.5658M |
| December 31, 2014 | -0.7461M |
| September 30, 2014 | 0.9232M |
| June 30, 2014 | 0.5108M |
| March 31, 2014 | 0.4225M |
| December 31, 2013 | 0.3739M |
| September 30, 2013 | 0.3211M |
| June 30, 2013 | 0.19M |
| March 31, 2013 | 0.2202M |
| December 31, 2012 | 0.4651M |
| September 30, 2012 | 0.5481M |
| June 30, 2012 | 0.5431M |
| March 31, 2012 | 0.418M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
0.898M
Minimum
Dec 2019
5.654M
Maximum
Dec 2023
2.906M
Average
2.895M
Median
Research and Development Expense (Quarterly) Benchmarks
| Hologic Inc | 64.10M |
| Perspective Therapeutics Inc | 9.275M |
| Spectral AI Inc | -- |
| Electromed Inc | 0.176M |
| Xtant Medical Holdings Inc | 0.636M |